P2 – 122. Fat, metabolism and obesity



Insulin-like Growth Factor-1 and Binding Protein-3 in Children with Metabolic Syndrome

Yoonji Lee, Moonbae Ahn, Seonhwa Lee, Yujung Choi, Seulki Kim, Shinhee Kim, Wonkyoung Cho, Kyoungsoon Cho, Minho Jung, and Byungkyu Suh* Department of Pediatrics, College of Medicine, Catholic University of Korea

* No conflicts of interest to we solve

				Univariat	e		Multivar	iate
Purpose			β	SE	p	β	SE	p
		AST (U/L)	-0.18	0.01	0.011*			
		ALT (U/L)	-0.01	<0.01	<0.001*	-0.01	<0.01	<0.001*
To examine the association of insulin-like growth factor-1 (IGF-1) and		UA (mg/dL)	-0.18	0.05	0.001*	-0.13	0.05	<0.001*
	IGF-1 SDS	TC (mg/dL)	-0.01	<0.01	0.012*	-0.01	<0.01	0.013*
insulin-like growth factor binding protein-3 (IGFBP-3) with metabolic		LDL-C (mg/dL)	-0.01	< 0.01	0.029*			
parameters of childhood obesity and assess its relationship with the		25(OH)D	-0.02	0.01	0.020*	-0.02	0.01	0.035*
prevalence of metabolic syndrome (MetS)		(ng/mL)						

A cross-sectional study of total 307 children and adolescents referred for growth assessment was performed. Subjects were divided into three groups based on body mass index (BMI) percentile for age and gender, and anthropometric profiles and biochemical data were collected examining their association with IGF-1 and IGFBP-3.

	BMI-SDS	0.09	0.05	0.048*			
IGFBP-3 SDS	25(OH)D	-0.02	0.01	0.001*	-0.02	0.01	0.003*
	(ng/mL)						
	AST (U/L)	-<0.01	<0.01	<0.001*	-<0.01	<0.01	<0.001*
	UA (mg/dL)	<0.01	<0.01	0.011*	<0.01	<0.01	0.009*
	TC (mg/dL)	<0.01	<0.01	<0.001*	<0.01	<0.01	<0.001*
IGF-1/IGFBP-3	LDL-C (mg/dL)	< 0.01	< 0.01	0.002*			
	HOMA-IR	<0.01	<0.01	0.001*	<0.01	<0.01	0.011 *

Table 2. Factors independently associated with IGFs

	Univariate		Multivariate			
	OR (95 % CI)	p	OR (95 % CI)	p		
IGF-1 SDS	0.62 (0.34-1.15)	0.128*	0.24 (0.09-0.63)	0.004*		
IGFBP-3 SDS	2.21 (1.17-4.19)	0.015*	5.28 (1.96-14.21)	0.001*		
IGF-1/IGFBP-3	1.09 (<0.01-10.00)	0.938				

Characteristics	Normoweight (n=207)	Overweight (n=36)	Obesity (n=64)	p
Mala/famala (number)	01/116	20/16	24/40	

Age (years)					
Height SDS	8.88±2.07	9.62±	2.64	9.40±2.76	0.094
BMI SDS	-0.82±1.00	-0.41±	1.25	0.51±1.08	<0.001*
IGF-1 SDS	-0.37±0.73	$1.07 \pm$	0.52	2.26±0.78	<0.001*
IGFBP-3 SDS	-0.31±1.11	-0.66±	1.36	-0.34±0.93	0.206
IGF-1/IGFBP-3	-0.92±1.16	-1.11±1.06		-0.65±1.07	0.116
FBS (mg/dL)	0.08±0.03	0.08±0.03		0.08±0.03	0.862
ALT (U/L)	94.85±7.71	95.14±7.65		93.09±5.93	0.219
TG (mg/dL)	16.07±6.53	24.06±	31.53	34.20±38.43	<0.001*
UA (mg/dL)	96.28±72.56	104.31±	:72.32	88.97±44.55	0.541
HDL-C (mg/dL)	4.16±0.93	4.88±	1.58	5.38±1.16	<0.001*
LDL-C (mg/dL)	58.41±11.32	55.22±	13.82	49.78±9.63	<0.001*
	90.48±24.30	99.04±	33.02	105.89±25.92	<0.001*
	Non-Me	+S		MotS	D
	Non-Me (n=296			MetS (n=11)	Р
	(n=296)		(n=11)	
BMI SDS	(n=296 0.24±1.2) 21		(n=11) 3.05±1.00	<0.001*
IGF-1 SDS	(n=296 0.24±1.2 -0.32±1.3) 21 10	-	(n=11) 3.05±1.00 -1.51±0.93	<0.001* <0.001*
IGF-1 SDS IGFBP-3 SDS	(n=296 0.24±1.2 -0.32±1.3 -0.90±1.3) 21 10 13	-	(n=11) 3.05±1.00 -1.51±0.93 -0.81±1.33	<0.001* <0.001* 0.798
IGF-1 SDS IGFBP-3 SDS IGF-1/IGFBP-3	(n=296 0.24±1.2 -0.32±1.3 -0.90±1.3 0.08±0.0) 21 10 13)3	-	(n=11) 3.05±1.00 -1.51±0.93 -0.81±1.33 0.80±0.03	<0.001* <0.001* 0.798 0.848
IGF-1 SDS IGFBP-3 SDS IGF-1/IGFBP-3 FBS (mg/dL)	(n=296 0.24±1.2 -0.32±1.3 -0.90±1.3 0.08±0.0 94.46±7.) 21 10 13)3 34	- - -	(n=11) 3.05±1.00 -1.51±0.93 -0.81±1.33 0.80±0.03 95.91±8.83	<0.001* <0.001* 0.798 0.848 0.524
IGF-1 SDS IGFBP-3 SDS IGF-1/IGFBP-3 FBS (mg/dL) ALT (U/L)	(n=296 0.24±1.2 -0.32±1.3 -0.90±1.3 0.08±0.0 94.46±7. 18.83±18) 21 10 13 03 34 .22	- - 2 7	(n=11) 3.05±1.00 -1.51±0.93 -0.81±1.33 0.80±0.03 95.91±8.83 3.09±49.03	<0.001* <0.001* 0.798 0.848
IGF-1 SDS IGFBP-3 SDS IGF-1/IGFBP-3 FBS (mg/dL) ALT (U/L) TG (mg/dL)	(n=296 0.24±1.2 -0.32±1.3 -0.90±1.3 0.08±0.0 94.46±7. 18.83±18 94.6767.9) 21 10 13 03 34 .22 98	- - 2 7 12	(n=11) 3.05±1.00 -1.51±0.93 -0.81±1.33 0.80±0.03 95.91±8.83 3.09±49.03 23.36±51.40	<0.001* <0.001* 0.798 0.848 0.524 0.004* 0.167
IGF-1 SDS IGFBP-3 SDS IGF-1/IGFBP-3 FBS (mg/dL) ALT (U/L) TG (mg/dL) UA (mg/dL)	(n=296 0.24±1.2 -0.32±1.3 -0.90±1.3 0.08±0.0 94.46±7. 18.83±18 94.6767.9 4.40±1.0) 21 10 13 03 34 .22 98 98	- - 7 12	(n=11) 3.05±1.00 -1.51±0.93 -0.81±1.33 0.80±0.03 -0.80±0.03 -0.91±8.83 3.09±49.03 -3.36±51.40 6.99±0.73	<0.001* <0.001* 0.798 0.848 0.524 0.004* 0.167 <0.001*
IGF-1 SDS IGFBP-3 SDS IGF-1/IGFBP-3 FBS (mg/dL) ALT (U/L) TG (mg/dL)	(n=296 0.24±1.2 -0.32±1.3 -0.90±1.3 0.08±0.0 94.46±7. 18.83±18 94.6767.9) 21 10 13 03 34 .22 98 98	- - 7 12	(n=11) 3.05±1.00 -1.51±0.93 -0.81±1.33 0.80±0.03 95.91±8.83 3.09±49.03 23.36±51.40	<0.001* <0.001* 0.798 0.848 0.524 0.004* 0.167

Table 3. Logistic regression model for the presence of metabolic syndrome

Result

Alanine aminotransferase (β =-0.01, p<0.01), uric acid (β =-0.13, p<0.01) and total cholesterol (β =-0.01, p=0.01) were inversely associated with IGF-1 while not related to IGFBP-3 or IGF-1 to IGFBP-3 ratio. The prevalence of MetS was 11.2 % (63.64 % in males; 36.36 % in females) among children who were older than 10 years. IGF-1 was lower in children with MetS compared to ones without MetS (-1.51±0.93 vs. -0.32±1.10, p<0.01) whereas showed no difference among three groups subdivided by BMI. Low IGF-1 (OR: 0.24, 95 % CI: 0.09-0.63, p<0.01) and high IGFBP-3 (OR: 5.28, 95 % CI: 1.96-14.21, p<0.01) were found to be risk factors of MetS. In children with MetS, no significant associations existed between IGF-1, IGFBP-3, or IGF-1 to IGFBP-3 ratio and any single component of MetS.

Table 1. General characteristics and obesity parameters of subjects

Abbreviations: 25(OHD), calcidiol; A1c, glycated hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FBS, fasting blood glucose; HDL-C, high density lipoprotein-cholesterol; IGF-1, insulin-like growth factor-1; IGF-BP3, insulin-like growth factor binding protein-3; LDL-C, low density lipoprotein-cholesterol; SDS, standard deviation score; TC, total cholesterol; TG, triglyceride; UA, uric acid *p < 0.05

Conclusion

IGF-1 and IGFBP-3 may be another key factors related to metabolic parameter of obesity and the presence of metabolic syndrome of youth. Elucidating the role of insulin-like growth factors might help to understand its metabolic action in obesity related condition.





